Skip to main content
Log in

Clinical significance of serum S100B levels in neurointensive care

Neurocritical Care Aims and scope Submit manuscript

Abstract

Objective

S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting.

Design

Prospective consecutive inclusion of patients.

Patients

A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study.

Interventions

Sampling for S100B was performed at admission and daily until patients were discharged from the NICU. S100B measurements were statistically compared to occurrence of secondary complications and outcome according to Glasgow Outcome Scale (GOS), with focus on clinical prediction.

Measurements and main results

17 of 79 patients (22%) had secondary neurological complications. Mean S100B levels were found to be an independent parameter associated with these complications (P = 0.03). Mean S100B levels were higher in patients with complications compared to those without on both the complication day (P = 0.033) and the day after (P = 0.015), but not the day prior to the complication (P = 0.62). S100B did not predict secondary neurological complication. Neither mean (P = 0.182) nor peak (P = 0.370) S100B levels were associated with or predicted outcome according to dichotomised GOS.

Conclusion

Daily S100B measurements are associated with secondary complications but not to outcome. However, daily S100B levels do not predict secondary complications, which limit the usefulness of this brain biomarker in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Qureshi AI. Evaluation of brain injury using a blood test: is there a role in clinical practice? Crit Care Med 2002;30(12):2778–9.

    Article  PubMed  Google Scholar 

  2. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33(7):637–68.

    Article  PubMed  CAS  Google Scholar 

  3. Ingebrigtsen T, Romner B, Marup-Jensen S, et al. The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 2000;14(12):1047–55.

    Article  PubMed  CAS  Google Scholar 

  4. Townend W, Dibble C, Abid K, et al. Rapid elimination of protein S-100B from serum after minor head trauma. J Neurotrauma 2006;23(2):149–55.

    Article  PubMed  Google Scholar 

  5. Vos PE, Lamers KJ, Hendriks JC, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62(8):1303–10.

    PubMed  CAS  Google Scholar 

  6. Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci 2003;21(3–4):177–90.

    PubMed  CAS  Google Scholar 

  7. Persson L, Hardemark HG, Gustafsson J, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18(5):911–8.

    PubMed  CAS  Google Scholar 

  8. Wiesmann M, Missler U, Hagenstrom H, et al. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir 1997;139(12):1155–60.

    Article  CAS  Google Scholar 

  9. Unden J, Christensson B, Bellner J, Alling C, Romner B. Serum S100B levels in patients with cerebral and extracerebral infectious disease. Scand J Infect Dis 2004;36(1):10–3.

    Article  PubMed  CAS  Google Scholar 

  10. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery 2001;48(6):1255–8, discussion 1258–60.

    Article  PubMed  CAS  Google Scholar 

  11. Unden J, Bellner J, Eneroth M, et al. Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma 2005;58(1):59–61.

    Article  PubMed  Google Scholar 

  12. Jonsson H, Johnsson P, Backstrom M, et al. Controversial significance of early S100B levels after cardiac surgery. BMC Neurol 2004;4(1):24.

    Article  PubMed  Google Scholar 

  13. Snyder-Ramos SA, Gruhlke T, Bauer H, et al. Cerebral and extracerebral release of protein S100B in cardiac surgical patients. Anaesthesia 2004;59(4):344–9.

    Article  PubMed  CAS  Google Scholar 

  14. Raabe A, Kopetsch O, Woszczyk A, et al. Serum S-100B protein as a molecular marker in severe traumatic brain injury. Restor Neurol Neurosci 2003;21(3–4):159–69.

    PubMed  CAS  Google Scholar 

  15. Gazzolo D, Michetti F, Bruschettini M, Marchese N, Lituania M, Mangraviti S, Pedrazzi E, Bruschettini P. Pediatric concentrations of S100B protein in blood: age- and sex-related changes. Clin Chem 2003;49(6 Pt 1):967–70.

    Article  PubMed  CAS  Google Scholar 

  16. Raabe A, Kopetsch O, Woszczyk A, et al. S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients. Neurol Res 2004;26(4):440–5.

    Article  PubMed  Google Scholar 

  17. Pleines UE, Morganti-Kossmann MC, Rancan M, et al. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001;18(5):491–8.

    Article  PubMed  CAS  Google Scholar 

  18. Rothoerl RD, Woertgen C, Brawanski A. S-100 serum levels and outcome after severe head injury. Acta Neurochir Suppl 2000;76:97–100.

    PubMed  CAS  Google Scholar 

  19. Woertgen C, Rothoerl RD, Brawanski A. Early S-100B serum level correlates to quality of life in patients after severe head injury. Brain Inj 2002;16(9):807–16.

    Article  PubMed  CAS  Google Scholar 

  20. Jonsson H, Johnsson P, Hoglund P, et al. Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 2000;14(6):698–701.

    Article  PubMed  CAS  Google Scholar 

  21. Unden J, Bellner J, Reinstrup P, et al. Serial S100B levels before, during and after cerebral herniation. Br J Neurosurg 2004;18(3):277–80.

    Article  PubMed  CAS  Google Scholar 

  22. Sen J, Belli A, Petzold A, et al. Extracellular fluid S100B in the injured brain: a future surrogate marker of acute brain injury? Acta Neurochir (Wien) 2005;147(8):897–900.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Leardal Foundation for acute medicine, the Åke Wibergs Foundation and the Crafoordska Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Johan Undén.

Additional information

This work was performed at the Neurointensive Care Unit at the department of Neurosurgery, Lund University Hospital, Lund, Sweden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Undén, J., Astrand, R., Waterloo, K. et al. Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 6, 94–99 (2007). https://doi.org/10.1007/s12028-007-0005-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-007-0005-0

Keywords

Navigation